| Schedule of research and development costs |
| | | | | | | | | | | | | | | Three Months Ended | | Three Months Ended | | Six Months Ended | | Six Months Ended | | | June 30, 2026 | | June 30, 2025 | | June 30, 2026 | | June 30, 2025 | | | | (In thousands) | Barzolvolimab/Anti-KIT Program | | $ | 54,946 | | $ | 42,645 | | $ | 117,110 | | $ | 82,348 | CDX-622 | | | 3,501 | | | 3,838 | | | 7,795 | | | 9,289 | Other Programs (a) | | | 9,095 | | | 7,713 | | | 15,638 | | | 15,173 | Total R&D Expense | | $ | 67,542 | | $ | 54,196 | | $ | 140,543 | | $ | 106,810 |
| (a) | Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs. |
| | | | | | | | | | | | | | | Three Months Ended | | Three Months Ended | | Six Months Ended | | Six Months Ended | | | June 30, 2026 | | June 30, 2025 | | June 30, 2026 | | June 30, 2025 | | | | (In thousands) | Personnel | | $ | 15,885 | | $ | 14,129 | | $ | 31,454 | | $ | 27,729 | Laboratory supplies | | | 2,593 | | | 1,544 | | | 4,051 | | | 3,712 | Facility | | | 1,178 | | | 1,398 | | | 2,118 | | | 2,803 | Product development (b) | | | 41,746 | | | 33,536 | | | 91,903 | | | 65,702 | Other expenses (c) | | | 6,140 | | | 3,589 | | | 11,017 | | | 6,864 | Total R&D expense | | $ | 67,542 | | $ | 54,196 | | $ | 140,543 | | $ | 106,810 |
| (b) | Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing. |
| (c) | Other expenses primarily include research and development consulting, insurance, licensing and software expenses. |
|